Publications

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI

This document outlines the updates to the LSDP’s testing requirements for Pompe disease, Gaucher disease (type 1), and mucopolysaccharidosis types I, II, and VI arising from the LSDP Expert Panel’s Medicines Reviews Recommendations.

Scroll down to access downloads and media.

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI [PDF - 109 KB] - 4 pages

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI [Word - 140 KB] - 4 pages

About this resource

Publication date:

27 September 2024

Publication type:

Report

Audience:

General public

Language:

English

Tags:

Medicines
Life Saving Drugs Program

Sub menu

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI

Updates to the clinical testing requirements for Pompe disease, Gaucher disease (type 1) and MPS types I, II and VI

About this resource

Help us improve health.gov.au